Close this search box.

Limited Distribution Deals Announced

Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely specify the specialty pharmacy(ies) selected as designated partner(s).

Here are three LD deals that have been recently publicly confirmed subsequent to the approvals.

Amber Specialty Pharmacy Selected to Dispense TZIELD (teplizumab), a Monoclonal Antibody Treatment to Delay Onset of Stage 3 Type 1 Diabetes in Patients with Stage 2 Type 1 Diabetes

OMAHA, Neb., — Amber Specialty Pharmacy announces that it will begin dispensing TZIELD (teplizumab), an anti-CD3 monoclonal antibody, to delay Stage 3 Type 1 Diabetes (T1D) in patients ages 8 years and older with Stage 2 T1D. Indication for individuals ages 8 years and older with Stage 2 T1D is categorized by the presence of two or more T1D-related autoantibodies and abnormal blood sugars. TZIELD™ is manufactured by Provention Bio, Inc., a New Jersey-based biopharma company.

Orsini Specialty Pharmacy Selected by Provention Bio as a Limited Distribution Partner for TZIELD

ELK GROVE VILLAGE, Ill., /PRNewswire/ — Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases, and gene therapies, has been selected by Provention Bio, Inc. a specialty pharmacy for TZIELD® (teplizumab). TZIELD is the first and only treatment indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adult and pediatric patients aged 8 years and older with Stage 2 T1D approved by the FDA.

ELAHERE Available at Biologics by McKesson

Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by ImmunoGen, Inc. as the sole specialty pharmacy provider for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.

This website uses cookies to ensure you get the best experience on our website.